Cementless Alumina-Alumina Total Hip and Hybrid

This is an interventional treatment trial for Rheumatoid Arthritis Read More

Inclusion Criteria:

• Patients with inflammatory tissue disorders (e.g. rheumatoid arthritis, lupus, etc), osteoarthritis, post-traumatic arthritis or secondary arthritis, or avascular necrosis.
• Less than 70 on preoperative HHS score
• Primary total hip replacement
• Patient is likely to be available for evaluation for the duration of the study.

Exclusion Criteria:

• Patients with physical conditions that would eliminate adequate implant support or prevent the use of an appropriately sized implant (e.g., tumor)
• Previous surgery that has adversely affected bone stock (such as some hip pinning or some osteotomies) or prior total hip replacement.

• Insufficient quality or quantity of bone resulting from conditions such as:

  • Cancer, where radiation has destroyed the available bonestock
  • Congenital dislocation
  • Metabolic bone disease of the upper femur or pelvis
  • Femoral osteotomy revision
  • Girdlestone revision
  • Active infection of the hip joint
  • Old or remote infection
  • Other conditions that lead to inadequate skeletal fixation
• Neurological conditions that might hinder patient's ability to follow study procedures, e.g., to restrict physical activities (e.g., Severe Parkinson's, CVA on affected side)

• Patient's mental condition that may interfere with his ability to give an informed consent or willingness to fulfill the required follow-up of the study

  • Mental illness
  • Senility
  • Drug Abuse
  • Alcoholism

• Conditions that place excessive demands on the implant

  • Charcot's joints
  • Muscle deficiencies
  • Multiple joint disabilities
  • Refusal to modify postoperative physical activities
  • Skeletal immaturity
  • Obesity (50% over recorded body weight mass index)
• Greater than or equal to 70 on preoperative HHS score